Abbott’s Panbio Rapid Antigen Test Receives CE Mark for Mass COVID-19 Screening
Shots: Endocyte to receive $24M/share in cash with total deal value of $2.1B. Novartis to get hold of all stocks with its RLT candidates Lu-PSMA-617 & Ac-PSMA-617 Lu-PSMA-617 is a novel treatment currently evaluated globally in P-III VISION clinical trial in men with mCRPC and demonstrated positive results in P-II (N=50) with mPFS (7.6 mos) […]Read More
